Yi Hu

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 27

Top Venues

Thoracic cancer

Cancer medicine

Medical oncology (Northwood, London, England)

Technology in cancer research & treatment

This page only lists publications with an associated author ORCID identifier.

Publications

Tao Li, Chao Chen, Lu Liu, Jiapei Qin, Lupeng Qiu, An Wang, Weiwei Dong, Gehan Zhang, Yao Li, Lei Zhao, Fan Zhang, Yi Hu
A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative. Cancer medicine 13 (3) (2024)
XiangFei Zhao, RuGang Zhao, JuYi Wen, Xia Zhang, ShanShan Wu, Juan Fang, JunPeng Ma, LiPin Gao, Yi Hu
Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment. Medical oncology (Northwood, London, England) 41 (5) (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer (2024)
XiangFei Zhao, RuGang Zhao, JuYi Wen, Xia Zhang, ShanShan Wu, Juan Fang, JunPeng Ma, LiPin Gao, Yi Hu
Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment. Medical oncology (Northwood, London, England) 41 (5) (2024)
XiangFei Zhao, RuGang Zhao, JuYi Wen, Xia Zhang, ShanShan Wu, Juan Fang, JunPeng Ma, LiPin Gao, Yi Hu
Bioinformatics-based screening and analysis of the key genes involved in the influence of antiangiogenesis on myeloid-derived suppressor cells and their effects on the immune microenvironment. Medical oncology (Northwood, London, England) 41 (5) (2024)
Tao Li, Chao Chen, Lu Liu, Jiapei Qin, Lupeng Qiu, An Wang, Weiwei Dong, Gehan Zhang, Yao Li, Lei Zhao, Fan Zhang, Yi Hu
A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative. Cancer medicine 13 (3) (2024)
Tao Li, Chao Chen, Lu Liu, Jiapei Qin, Lupeng Qiu, An Wang, Weiwei Dong, Gehan Zhang, Yao Li, Lei Zhao, Fan Zhang, Yi Hu
A multicenter, real-world study on effectiveness and safety of first-line modified PD-1 inhibitors with chemotherapy in advanced non-small cell lung cancer (aNSCLC) with drive gene-negative. Cancer medicine 13 (3) (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 15 (5) (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 15 (5) (2024)
Gen Lin, Zhijie Wang, Qian Chu, Yi Hu, Dingzhi Huang, Jun Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Liu Yutao, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Qiaofeng Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Rechallenge of immune checkpoint inhibitors in advanced non-small cell lung cancer. Thoracic cancer 15 (5) (2024)
Tao Li, Wen-Yu Yang, Ting-Ting Liu, Yao Li, Lu Liu, Xuan Zheng, Lei Zhao, Fan Zhang, Yi Hu
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Technology in cancer research & treatment 22 (2023)
Tao Li, Wen-Yu Yang, Ting-Ting Liu, Yao Li, Lu Liu, Xuan Zheng, Lei Zhao, Fan Zhang, Yi Hu
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Technology in cancer research & treatment 22 (2023)
Shu Zhao, Peng Song, Gang Zhou, Dong Zhang, Yi Hu
METTL3 promotes the malignancy of non-small cell lung cancer by N6-methyladenosine modifying SFRP2. Cancer gene therapy (2023)
Qingyan Liu, Rong Li, Lingling Li, Gaokun Wang, Shiyu Ji, Xuan Zheng, Xiaodong Jia, Haitao Tao, Yi Hu
Efficacy and safety of anti-PD-1 monotherapy versus anti-PD-1 antibodies plus lenvatinib in patients with advanced hepatocellular carcinoma: a real-world experience. Therapeutic advances in medical oncology 15 (2023)
Fuxin Han, Zhaozhen Wu, Jiaxin Chen, Meicen Liu, Yi Hu
The efficacy and safety of chemotherapy with or without anti-PD-1 for the first-line treatment of advanced urothelial carcinoma. Cancer medicine (2023)
Tao Jiang, Qiqi Jin, Jiahao Wang, Feng-Ying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, Qi-Ming Wang, Yue-Yin Pan, Jian-Ying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yun-Peng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiu-Wei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luo-Nan Chen, Cai-Cun Zhou, Shengxiang Ren
HLA-I evolutionary divergence confers response to PD-1 blockade plus chemotherapy in untreated advanced non-small-cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Dingzhi Huang, Gen Lin, Qian Chu, Yi Hu, Jun Wang, Zhijie Wang, Fan Yang, Wen-Zhao Zhong, Cheng-Zhi Zhou, Bo Zhu, Xinghao Ai, Baoshan Cao, Yabing Cao, Mingqiu Chen, Xiaohui Chen, Tianqing Chu, Jianchun Daun, Yun Fan, Yong Fang, Shuitu Feng, Weineng Feng, Hui Guo, Cheng-Bo Han, Yong He, Shaodong Hong, Jie Hu, Meijuan Huang, Yan Huang, Da Jiang, Kan Jiang, Richeng Jiang, Bo Jin, Shi Jin, Jisheng Li, Min Li, Ziming Li, Chao Li, Jie Lin, Anwen Liu, Si-Yang Maggie Liu, Yutao Liu, Zhefeng Liu, Zhe Liu, Zhenhua Liu, Zhentian Liu, Zhigang Liu, Yuping Lu, Tang-Feng Lv, Zhiyong Ma, Qian Miao, Min Peng, Xingxiang Pu, Xiu Bao Ren, Jianzhen Shan, Jinlu Shan, Peng Shen, Bo Shen, Meiqi Shi, Yong Song, Zhengbo Song, ChunXia Su, Jianguo Sun, Panwen Tian, Jinliang Wang, Feng Wang, Huijuan Wang, Jialei Wang, Qian Wang, Wen-Xian Wang, Yan Wang, Lin Wu, Fang Wu, Yang Xia, Congying Xie, Conghua Xie, Tao Xin, Jianping Xiong, Haipeng Xu, Song Xu, Yiquan Xu, Bin Xu, Chun-Wei Xu, Xiaolong Yan, Zhenzhou Yang, Wenxiu Yao, Yao Yu, Ye Feng, Zongyang Yu, Yongfeng Yu, Dongsheng Yue, Haibo Zhang, HongMei Zhang, Li Zhang, Longfeng Zhang, Qiuyu Zhang, Tong-Mei Zhang, Bicheng Zhang, Jun Zhao, Mingfang Zhao, Xiaobin Zheng, Fengqiao Zhong, Jin Zhou, Penghui Zhou, Zhengfei Zhu, Juntao Zou, Zihua Zou
Clinical definition of secondary resistance to immunotherapy in non-small cell lung cancer. Thoracic cancer (2023)
Tao Li, Wen-Yu Yang, Ting-Ting Liu, Yao Li, Lu Liu, Xuan Zheng, Lei Zhao, Fan Zhang, Yi Hu
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China. Technology in cancer research & treatment 22 (2023)
Zhi-Qiang Ma, Ying-Tong Feng, Kai Guo, Dong Liu, Chang-Jian Shao, Ming-Hong Pan, Yi-Meng Zhang, Yu-Xi Zhang, Di Lu, Di Huang, Fan Zhang, Jin-Liang Wang, Bo Yang, Jing Han, Xiao-Long Yan, Yi Hu
Melatonin inhibits ESCC tumor growth by mitigating the HDAC7/β-catenin/c-Myc positive feedback loop and suppressing the USP10-maintained HDAC7 protein stability. Military Medical Research 9 (1) (2022)
Chao Wu, Jiajin Zhang, Kuan Wang, Mengjiao Fan, Yi Hu
FAM117A Is a New Prognostic Marker of Lung Adenocarcinoma and Predicts Sensitivity to PD0332991. Evidence-based complementary and alternative medicine : eCAM 2022 (2022)
Zhaozhen Wu, Haitao Tao, Sujie Zhang, Xiao Wang, Junxun Ma, Ruixin Li, Zhefeng Liu, Jinliang Wang, Pengfei Cui, Shixue Chen, Huang Di, Ziwei Huang, Xuan Zheng, Yi Hu
Efficacy and safety of anti-PD-1-based therapy in combination with PARP inhibitors for patients with advanced solid tumors in a real-world setting. Cancer immunology, immunotherapy : CII 70 (10) (2021)
Lingling Li, Zhibo Zhang, Yi Hu
Neuron - specific enolase predicts the prognosis in advanced small cell lung cancer patients treated with first-line PD-1/PD-L1 inhibitors. Medicine 100 (36) (2021)
Yaping Long, Qi Xiong, Qi Song, Yao Li, Xiaoyan Li, Boyu Qin, Ziwei Huang, Yi Hu, Bo Yang
Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib. Thoracic cancer 13 (3) (2021)
Baolin Liu, Xueda Hu, Kaichao Feng, Ranran Gao, Zhiqiang Xue, Sujie Zhang, Yuanyuan Zhang, Emily Corse, Yi Hu, Weidong Han, Yuanyuan Zhang
Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer. Nature cancer 3 (1) (2021)
Qi Xiong, Ziwei Huang, Lingli Xin, Boyu Qin, Xiao Zhao, Jing Zhang, Weiwei Shi, Bo Yang, Guoqing Zhang, Yi Hu
Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase. Cancer immunology, immunotherapy : CII 70 (3) (2020)
Shixue Chen, Lingling Li, Fan Zhang, Yu Wang, Yi Hu, Lei Zhao
Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy. Journal of immunology research 2019 (2019)
Zhibo Zhang, Ye Li, Xiang Yan, Qi Song, Guoqiang Wang, Yi Hu, Shunchang Jiao, Jinliang Wang
Pretreatment lactate dehydrogenase may predict outcome of advanced non small-cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis. Cancer medicine 8 (4) (2019)

Yi Hu.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Yi Hu